Understanding the EGFR mutation
aids the fight against lung cancer

Dr Yamaoka studies the mechanisms of drug resistance in lung cancer patients.

Genetic mutations are known to be responsible for several different types of cancer. One type, known as non-small cell lung cancer, is sometimes caused by mutations in a gene called EGFR. A group of drugs called tyrosine kinase inhibitors are often used to treat patients with this type of cancer. Unfortunately, patients can develop genetic alterations, namely mutation, amplification (an […]

Read More…